Sugi Predict

Sugi Predict / Compounds / SCHEMBL1266147

SCHEMBL1266147

SCHEMBL1266147

[CH]1CCN(c2ccccn2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLD1 Q13393 1/20 0.63
▸ KDM4E B2RXH2 3/20 0.56
▸ GRIN2D O15399 1/20 0.53
▸ GRIN3B O60391 1/20 0.53
▸ GRIN1 Q05586 1/20 0.53
▸ GRIN2A Q12879 1/20 0.53
▸ GRIN2B Q13224 1/20 0.53
▸ GRIN2C Q14957 1/20 0.53
▸ GRIN3A Q8TCU5 1/20 0.53
▸ ALDH1A1 P00352 4/20 0.53
▸ MAPT P10636 2/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ USP2 O75604 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ MAPK1 P28482 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4065717 0.88 PLD1 (0.55) PLD1KDM4EGRIN2DGRIN3BGRIN1
SCHEMBL21353591 0.87 — —
SCHEMBL29857922 0.87 PLD1 (0.73) PLD1KDM4EGRIN2DGRIN3BGRIN1
SCHEMBL15800694 0.87 PLD1 (0.73) PLD1KDM4EGRIN2DGRIN3BGRIN1
SCHEMBL29462629 0.83 PLD1 (0.68) PLD1KDM4EGRIN2DGRIN3BGRIN1
SCHEMBL230367 0.83 PLD1 (0.68) PLD1KDM4EGRIN2DGRIN3BGRIN1
SCHEMBL157489 0.83 PLD1 (0.68) PLD1KDM4EGRIN2DGRIN3BGRIN1
SCHEMBL18228078 0.83 PLD1 (0.68) PLD1KDM4EGRIN2DGRIN3BGRIN1
SCHEMBL3154137 0.81 PLD1 (0.66) PLD1KDM4EGRIN2DGRIN3BGRIN1
SCHEMBL29389926 0.81 PLD1 (0.66) PLD1KDM4EGRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416205-A1 COMPOUNDS, COMPOSITIONS, AND METHODS TENVIE THERAPEUTICS, INC. 2023-12-28 — — US claimed
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2023-11-02 — — US claimed
EP-4247376-A1 COMPOUNDS, COMPOSITIONS, AND METHODS Denali Therapeutics Inc. (US) 2023-09-27 — — EP claimed
CN-116507608-A Compounds, compositions, and methods 戴纳立制药公司 2023-07-28 — — CN claimed
EP-4146623-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF Alectos Therapeutics Inc. (CA) 2023-03-15 — — EP claimed
CN-115803025-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2023-03-14 — — CN claimed
WO-2022109268-A1 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2022-05-27 — — WO claimed
WO-2021224864-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2021-11-11 — — WO claimed
US-20210253562-A1 ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2021-08-19 — — US claimed
WO-2020008317-A1 ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2020-01-09 — — WO claimed
CN-1432020-A Purine derivatives PFIZER LTD (US) 2003-07-23 — — CN claimed
EP-1296996-A1 PURINE DERIVATIVES Pfizer Limited (GB) 2003-04-02 — — EP claimed
EP-1292604-A1 2-AMINOCARBONYL-9H-PURINE DERIVATIVES Pfizer Limited (GB) 2003-03-19 — — EP claimed
US-20020058641-A1 2-aminocarbonyl-9H-purine derivatives PFIZER INC. 2002-05-16 — — US claimed
US-20020032168-A1 Purine derivatives PFIZER INC. 2002-03-14 — — US claimed
WO-2002000676-A1 PURINE DERIVATIVES PFIZER LIMITED (GB) 2002-01-03 — — WO claimed
WO-2001094368-A1 2-AMINOCARBONYL-9H-PURINE DERIVATIVES PFIZER LIMITED (GB) 2001-12-13 — — WO claimed
US-6326359-B1 PURINE DERIVATIVES PFIZER INC 2001-12-04 — — US claimed
EP-1121372-A1 ADENINE DERIVATIVES Pfizer Limited (GB) 2001-08-08 — — EP claimed
WO-2000023457-A1 ADENINE DERIVATIVES PFIZER LIMITED (GB) 2000-04-27 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA PLD1 1344/4885KDM4E 2704/4885GRIN2D 4334/4885
US-20020032168-A1 Purine derivatives ADORA2A, ADORA1, ADORA3 PLD1 450/4885KDM4E 4374/4885GRIN2D 1619/4885
US-20230416205-A1 COMPOUNDS, COMPOSITIONS, AND METHODS NLRP3, NLRP1, NOD1 PLD1 2542/4885KDM4E 3822/4885GRIN2D 2039/4885
US-20210253562-A1 ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS PTGER3, FFAR3, PTGES3 PLD1 811/4885KDM4E 2587/4885GRIN2D 1068/4885
US-20020058641-A1 2-aminocarbonyl-9H-purine derivatives PNP, NUDT1, SLC29A1 PLD1 2427/4885KDM4E 2432/4885GRIN2D 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.